Bleeding and Clotting Disorders Institute   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Peoria IL United States (2010)

Organization Overview

First Clinical Trial
2022
NCT05500807
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bleeding and Clotting Disorders Institute Peoria, Illinois

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Bleeding and Clotting Disorders Institute (0) Acquired (1)

antihemophilic factor viii (Recombinant) (Adynovate) (1 trial)

Drugs in Phase 1 Trials (1)

emicizumab (Hemlibra) (1 trial)

Indications

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2